Nuclease Probe Technologies raises $500,000 from Breakout Labs to Support Development of Rapid Antibiotic Susceptibility Testing for Bloodstream Infections

Lowell, MA — Nuclease Probe Technologies, Inc., a company pioneering a precision medicine approach to matching patients with the most effective antibiotics to treat deadly bloodstream infections, announces the investment by Breakout Labs, a Thiel Foundation fund that backs scientist-entrepreneurs transitioning scientific breakthroughs out of the lab and into the market.

“I’m absolutely thrilled to have the confidence and support of Breakout Labs as investors in Nuclease Probe Technologies,” said Dr. James McNamara, founder and chief executive officer of Nuclease Probe Technologies, Inc. “Breakout Labs is known for their deep scientific expertise and support of disruptive technologies like our nuclease activated probe, or NucAP™ technology. They will bring technical expertise, domain knowledge, and industry connections to help support the growth and direction of our company. The capital will help our team develop simple blood tests to detect bacterial pathogens and determine the most effective treatment.”

With this funding NPT will commence operations at the Massachusetts Medical Device Development Center — M2D2 located in Lowell, Massachusetts. Continue reading…